Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inverness alters name to Alere

This article was originally published in The Tan Sheet

Executive Summary

Medical diagnostic firm Inverness Medical Innovations seeks shareholder approval to rechristen itself Alere - the name of its health management services business. The change announced May 18 reflects the firm's continuing evolution toward integrated health management and therapeutic services and away from legacy operations, such as the nutritionals business it divested in January (1"The Tan Sheet" Jan. 25, 2010, In Brief). Inverness, based in Waltham, Mass., also announced first-quarter net revenue of $515.3 million, a 21.2 percent gain. Revenue from the consumer diagnostics unit fell 24 percent to $24.7 million in the January-March period, Inverness said April 28. However, product revenues from the company's joint venture with Procter & Gamble rose 15 percent to $55.9 million. Inverness' quarterly net income jumped 118.5 percent to $14.2 million

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104138

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel